Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
![]() |
![]() ![]() |
![]() BAZINET, Michel, ANDERSON, Mark, PÂNTEA, Victor, PLĂCINTĂ, Gheorghe, MOSCALU, Iurie, CEBOTARESCU, Valentin, COJUHARI, Lilia, JIMBEI, Pavlina, IAROVOI, Liviu, SMESHNOI, Valentina, MUSTEAŢĂ, Tatiana, JUCOV, Alina, DITTMER, Ulf, GERSCH, Jeffrey, HOLZMAYER, Vera, KUHNS, Mary C., CLOHERTY, Gavin A., VAILLANT, Andrew. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection. In: Hepatology Communications, 2022, vol. 6, pp. 1870-1880. ISSN 2471-254X. DOI: https://doi.org/10.1002/hep4.1951 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Hepatology Communications | |
Volumul 6 / 2022 / ISSN 2471-254X | |
|
|
DOI:https://doi.org/10.1002/hep4.1951 | |
Pag. 1870-1880 | |
Vezi articolul | |
Rezumat | |
Nucleic acid polymers block the assembly of hepatitis B virus (HBV) subviral particles, effectively preventing hepatitis B surface antigen (HBsAg) replenishment in the circulation. Nucleic acid polymer (NAP)–based combination therapy of HBV infection or HBV/hepatitis D virus (HDV) co-infection is accompanied by HBsAg clearance and seroconversion, HDV-RNA clearance in co-infection, and persistent functional cure of HBV (HBsAg < 0.05 IU/ml, HBV-DNA target not dected, normal alanine aminotransferase) and persistent clearance of HDV RNA. An analysis of HBsAg isoform changes during quantitative HBsAg declines (qHBsAg), and subsequent treatment-free follow-up in the REP 301/REP 301-LTF (HBV/HDV) and REP 401 (HBV) studies was conducted. HBsAg isoforms were analyzed from frozen serum samples using Abbott Research Use Only assays for HBsAg isoforms (large [L], medium [M], and total [T]). The relative change over time in small HBsAg relative to the other isoforms was inferred by the change in the ratio over time of T-HBsAg to M-HBsAg. HBsAg isoform declines followed qHBsAg declines in all participants. No HBsAg isoforms were detectable in any participants with functional cure. HBsAg declines > 2 log10 IU/ml from baseline were correlated with selective clearance of S-HBsAg in 39 of 42 participants. Selective S-HBsAg decline was absent in 9 of 10 participants with HBsAg decline < 2 log10 IU/ml from baseline. Mild qHBsAg rebound during follow-up [removed]. |
|
Cuvinte-cheie alanine aminotransferase, hepatitis B surface antigen, monoclonal antibody, Nucleic Acid Polymer, polymer, tenofovir disoproxil, unclassified drug, virus DNA, virus RNA |
|
|